Stock HOWL WEREWOLF THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Delayed Nasdaq
Other stock markets
 16:00:00 2024-06-18 EDT 		5-day change 1st Jan Change
2.89 USD -7.67% Intraday chart for Werewolf Therapeutics, Inc. -9.69% -25.13%
06-01 Werewolf Therapeutics to Present Data from Ongoing Phase 1/1B Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors CI
05-23 Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
AQ
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
AQ
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
AQ
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
AQ
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
AQ
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
AQ
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
AQ
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
AQ
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
AQ
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
AQ
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
AQ
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
AQ
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
AQ
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
AQ
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
AQ
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HOWL Stock
  4. News Werewolf Therapeutics, Inc.
  5. Press Releases